Oral GLP-1 medications, such as Vegovy (semaglutide), have previously become popular for weight loss. The new drug orforglipron recently showed better results than Vegovy in a larger study. In the Phase III trial, participants with an average weight of 97 kg lost 6-8 percent of their weight when taking orforglipron, while those taking Vegovy were able to lose only 4-5 percent of their weight.

The demand for anti-obesity medicines is increasing rapidly across the world. It is estimated that this market will be worth approximately US$30 billion in 2024 and will exceed US$100 billion by 2030-2034. The main reasons for this are increasing obesity and popularity of GLP-1 drugs.